



A**B**

Figure S1. Analysis of *B2M* on-target locus and protein outcome in M HYPO clone: (A) Analysis of *B2M* on-target locus using the Tracking of Indels by Decomposition online tool. (B) Molecular modelling of $\beta 2M$ protein (P61769) with the p.delI27-Y30 deletion as a consequence of the indel mutation following CRISPR/Cas9 gene editing.




Figure S2. Characterization of the 19L HYPO iPSC line. (A) Schematic representation of CRISPR/Cas9 strategy to target *B2M* and *CIITA* genes. (B) Chromatograms showing Sanger sequencing of *B2M* and *CIITA* single alleles isolated by TOPO TA cloning of the *CIITA* and *B2M* compound heterozygous 19L HYPO clone and alignment to the WT sequence using the SnapGene software. (C) Bright-field image showing 19L HYPO cell morphology. Scale bar: 100 μ m. (D) Karyotype analysis of M HYPO iPSC clone. (E) Analysis of transcript levels of pluripotency marker genes *OCT4*, *NANOG* and *SOX2* by qRT-PCR. The 802-30F iPSC (WT) clone was taken as reference sample. Data are expressed as the mean \pm standard deviation (SD) of three independent biological experiments. (F) Immunostaining analysis for pluripotency markers. Nuclei were stained with DAPI. Scale bars: 50 μ m. (G) Immunofluorescence for endodermal marker α -fetoprotein (AFP), ectodermal marker β -TUBULIN and mesodermal marker α -smooth muscle actin (α -SMA) showing iPSC trilineage differentiation potentiality. Scale bars: 50 μ m.




Figure S3. Analysis of 19L HYPO ability to differentiate towards endothelial-like cells (EC-19L HYPO), hepatocyte-like cells (HLC-19L HYPO) and hepatic stellate-like cells (HSC-19L HYPO). (A) Representative immunofluorescence images showing the expression of CD144 and α -SMA on iPSC-ECs from 19L HYPO pre- and post-sorting, (B) the expression of the endothelial markers CD144 and vWF (left) in EC-19L HYPO and of F-Actin in capillary-like structures formed following the in vitro tube formation assay (right). (C) Representative overlay histogram plots of flow cytometric analysis of HLA-DR, HLA-ABC and CD47 in IFN γ -treated endothelial cells derived from WT (black) and M HYPO cells (blue). (D) Representative immunofluorescence images showing the expression of the hepatocyte markers ASGPR1, ALB, HNF4 α and AFP in HLC-19L HYPO cells. (E) Analysis of ICG uptake (left) and PAS staining showing glycogen storage (right) in differentiated cells. (F) Protein expression of the HSC markers PCDH7, PDGFR β , NCAM and vimentin in HSC-19L HYPO cells

by immunofluorescence analysis. (G) Representative overlay histogram plots of flow cytometry analysis of iPSC-HSC PDGFR β -positive cells and vitamin A-positive cells at the end of a 4-day retinol treatment. The red line divides negative (on the left) from positive (on the right) marker expression.

Table S1: List of primers used to amplify and sequence on-target and off-target sites

Target	Sequence
On target: B2M ENSG00000166710 chr15:44715428-44715450	<u>B2M gPCR F:</u> CCCAGCCTGTCGTGATACTTGT <u>B2M gPCR R:</u> TGCGGCATCTCAAACCTGA <u>B2M seq F:</u> GAGAGCCTCCAGAGAAAGGC <u>B2M seq R:</u> TGCTCAACTGCAGGGAAACT
OT#1: MACC1 ENSG00000183742 chr7:20170788-20170810	<u>OT#1 gPCR F:</u> TTCACTGTCACTTGGCGG <u>OT#1 gPCR R:</u> ACTGTAGGGTCCTCACTTGC <u>OT#1 seq1 F:</u> TACTGTTGCACACCGTTCTGT <u>OT#1 seq2 F:</u> ATCCTGGCTAACACGGTGAA
OT#2: LINC00992/AC114945.1 ENSG00000248663 chr5:117415509-117546298	<u>OT#2 gPCR F:</u> TGTGCCACCTGAAAATTGCG <u>OT#2 gPCR R:</u> GCCTCAGTAGTGCACATGGT <u>OT#2 seq1 R:</u> GGTAGAAGATCCAACCAACTCT <u>OT#2 seq2 F:</u> TGTGCCACCTGAAAATTGCG
OT#3: AL034395.1-KAZN ENSG00000280763 chr1:14637585-14637607	<u>OT#3 gPCR F:</u> GTGACAGTGACGGGATAAGT <u>OT#3 gPCR R:</u> CCCGTGAACCTTCTAAGCCC <u>OT#3 seq1 F:</u> GAGAAGGGTGGGGACAAGG <u>OT#3 seq2 R:</u> AAGGAGATCAGAGGGAGGT
OT#4: LINC01493 ENSG00000254562 11:38646451-38686323:1	<u>OT#4 gPCR F:</u> AAGAAAGCTCTGTGTCATCCTGG <u>OT#4 gPCR R:</u> GACCCCTTCTCCCTGAAGTGTG <u>OT#4 seq1 F:</u> AAGCATACTGAGCAAAAGTGCAG <u>OT#4 seq2 R:</u> TGTAAAGAAACTGTGTGTTGCAT
OT#5: RP11-21B23.1-RP11-21B23.2 ENSG00000261393 chr16:50378641-50378663	<u>OT#5 gPCR F:</u> CGGGGCTCCCTCAGTAATA <u>OT#5 gPCR R:</u> GGGAAAGCACTCTGACGCTC <u>OT#5 seq1 R:</u> CCCTCCACGGCTCTGTAAT <u>OT#5 seq2 R:</u> GGGAAAGCACTCTGACGCTC
OT#6: TTC8 ENSG00000165533 chr14:88878928-88878950	<u>OT#6 gPCR F:</u> TGTTAATGGGACAGGACACTC <u>OT#6 gPCR R:</u> GCACAGAAGCCAGAAGTTACG <u>OT#6 seq1 R:</u> GCACAGAAGCCAGAAGTTACG <u>OT#6 seq2 R:</u> GCACAGAAGCCAGAAGTTACG
OT#7: RYR3 ENSG00000198838 15:33310962-33866121	<u>OT#7 gPCR F:</u> GAGAGACAGGGCAAAGACCC <u>OT#7 gPCR R:</u> AGGCAAAACTGGAACCCACA <u>OT#7 seq1 F:</u> ACAGAAGACTTAGCCAGTTGC <u>OT#7 seq2 R:</u> GAGGAGGTGGCACTAAA
OT#8: SETD7 ENSG00000145391 4:139495941-139606699	<u>OT#8 gPCR F:</u> TTGTTAACCTGTTACTGCAGGC <u>OT#8 gPCR R:</u> ATACAGTTCTGCAAGGATTCCA <u>OT#8 seq1 F:</u> TTGGCCCTTGTGAAATTGGGATTA <u>OT#8 seq2 R:</u> TGGTAACGACACGCTTGAA

Abbreviations: OT, off-target; F, forward; R, reverse; gPCR, genomic polymerase chain reaction; seq, sequencing

Table S2: List of Taqman probes and primers

Catalog number	Gene Symbol	Description
Hs0275891_g1	<i>GAPDH</i>	Glyceraldehyde-3-Phosphate Dehydrogenase
Hs00742896_s1	<i>Oct4</i>	POU Class 5 Homeobox 1
Hs02387400_g1	<i>Nanog</i>	Nanog Homeobox
Hs00602736_s1	<i>SOX2</i>	SRY-Box Transcription Factor 2
Hs00610080_m1	<i>Brachyury (T)</i>	T-Box Transcription Factor T
RefSeq	Gene Symbol	Sequence 5'-3'
NM_000194.3	Hs <i>HPRT</i>	Fwd: GGCAGTATAATCCAAAGATGGTCA Rev: TCCTTTCACCGAACAGCTTG
NM_022454.4	Hs <i>SOX17</i>	Fwd: GGCGCAGCAGAACATCCAGA Rev: CCACGACTTGCCCCAGCAT
NM_001008540.2	Hs <i>CXCR4</i>	Fwd: TCCATTCTTGCCTTTGC Rev: TGTCGCTCATGCTTCAGTT
NM_178849.3	Hs <i>HNF4α</i>	Fwd: ACTACATCAACGACCAGCAGT Rev: ATCTGCTCGATCATCTGCCAG
NM_001134.3	Hs <i>AFP</i>	Fwd: AAATGCGTTCTCGTTGCTT Rev: GCCACAGGCCAATAGTTGT
NM_000477.7	Hs <i>ALB</i>	Fwd: GCACAGAACCTGGTGAACAG Rev: ATGGAAGGTGAATGTTTCAGCA
NM_001173523.2	Hs <i>PCDH7</i>	Fwd: TGTGGGAGCAGGAGACAACA Rev: CACTCTACGAAATGGCTGTTGC
NM_002609.3	Hs <i>PDGFRB</i>	Fwd: ATCAGCAGCAAGGACCCAT Rev: CAGGAGAGACAGCAACAGCA
NM_001927.4	Hs <i>DES</i>	Fwd: CAACAAGAACAGCACGCC Rev: GGGATCGTTAGTGCCCTCA

Table S3: List of primary and secondary antibodies

Target Antigen	Company	Catalog Number
OCT3/4 (Octamer-binding transcription factor 3/4)	Santa Cruz	sc-5279, RRID:AB_628051
NANOG (Nanog homeobox)	Santa Cruz	sc-33759, RRID:AB_2150401
TRA-1-60 (T cell receptor alpha locus-1-60)	Millipore	MAB4360, RRID:AB_2119183
TRA-1-81 (T cell receptor alpha locus-1-81)	Millipore	MAB4381, RRID:AB_177638
SSEA-3 (Stage-specific embryonic antigen 3)	Santa Cruz	sc-21703, RRID:AB_628288
SSEA-4 (Stage-specific embryonic antigen 4)	Santa Cruz	sc-21704, RRID:AB_628289
α -SMA (α -Smooth muscle actin)	Sigma	C6198, RRID:AB_476856
AFP (Alpha-fetoprotein)	Santa Cruz	sc-51506, RRID:AB_626514
β -TUBULIN	Millipore	CBL412X, RRID:AB_1977541
CD144 (vascular endothelial-cadherin)	R&D	AF938, RRID:AB_355726
vWF (von Willebrand Factor)	DAKO	A0082, RRID:AB_2315602
ASPGR1 (Asialoglycoprotein receptor)	Santa Cruz	sc-52623, RRID:AB_667806
HNF4 α (Hepatocyte nuclear factor 4 alpha)	Abcam	ab92378, RRID:AB_10562973
ALB (Albumin)	Bethyl	A80-129A, RRID:AB_67016
PCDH7 (Protocadherin 7)	Abcam	ab139274, RRID:AB_2868608
PDGFR β (Platelet-derived growth factor receptor β)	Abcam	ab32570, RRID:AB_777165
NCAM (Neural cell adhesion molecule)	Millipore	AB5032, RRID:AB_2291692
VIMENTIN	Thermo Fisher Scientific	PA5-27231, RRID:AB_2544707
Secondary Antibodies		
Donkey anti-Rabbit IgG (H + L) Alexa Fluor 546	Thermo Fisher Scientific	A10040, RRID:AB_2534016
Goat anti-Mouse IgM Alexa Fluor 488	Thermo Fisher Scientific	A-21042, RRID: AB_2535711
Donkey anti-Mouse IgG (H + L) Alexa Fluor 546	Thermo Fisher Scientific	A10036, RRID: AB_2534012
Goat anti-Rat IgM, Alexa Fluor 488	Thermo Fisher Scientific	A-21212, RRID: AB_2535798
Donkey anti-Goat IgG (H + L) Alexa Fluor 488	Thermo Fisher Scientific	A11055, RRID:AB_2411589
Goat anti-Rabbit IgG (H + L) Alexa Fluor 488	Thermo Fisher Scientific	A-21206, RRID: AB_2289872